We work collaboratively with clients as a cross-functional interdisciplinary team to advance to the regulatory approval process. While working with InfinixBio, you will be involved in every step of the process, maintaining control and direction of the projects.
In the early stages of drug discovery, developing robust assays is a critical part of your long-term success. If you are in the initial discovery phase, InfinixBio can work collaboratively with your team to customize project requirements, including everything from target characterization to lead optimization.
Our protein biochemistry capabilities include the development of protein, enzyme, and immunoassays, as well as protein purification, modification (e.g. pegylation), characterization, and stabilization.
InfinixBio scientists have extensive experience in genetic engineering technology and Molecular Biology. Specific applications that we have developed include chromosomal gene modification of E. coli to construct highly efficient bioproduction strains; sophisticated genetic modification of mammalian cell lines; design, construction and testing of multifunctional engineered proteins; and modification of therapeutic bioproduction processes to improve product yields and reduce costs. We work collaboratively to efficiently meet our client’s needs for genetically engineered solutions.
Our scientific insights help us solve challenging problems in cell biology, including:
Target identification and validation are foundational steps that focus on discovering and confirming biological molecules that play a critical role in a disease process and can be modulated by a drug. We use genomic, proteomic, or bioinformatic approaches to uncover potential targets associated with disease onset or progression. Once identified, we use in vitro experiments, assay development, and genetic manipulation to demonstrate a clear link between the target and the disease. Our commitment to successful target validation increases the likelihood that your drug development will be effective and safe, forming a crucial basis on the FDA pathway.
Hit identification is a key step that involves discovering chemical compounds—known as "hits"—that interact with a validated biological target and produce a desired biological effect. We then subject identified hits to confirmatory assays and preliminary assessments of potency, selectivity, and toxicity.
Hit-to-lead development support is a critical phase where initial “hit” compounds are refined into “lead” compounds with improved drug-like properties. We use structure-activity relationship (SAR) studies, in vitro ADME (absorption, distribution, metabolism, and excretion) profiling, and preliminary toxicity assessments to identify a small number of lead compounds that demonstrate optimal efficacy and safety characteristics.
